Updated Aug 15 at 10:48am ET.
Follow Incannex Healthcare Limited to never miss an important update.
Incannex is moving forward with its DReAMzz study, which aims to confirm the right dose for its lead drug candidate, IHL-42X. This drug targets obstructive sleep apnea, a common condition where breathing repeatedly stops and starts during sleep. The company has already received Fast Track status from regulators, a process designed to speed up the review of drugs that treat serious conditions.
For a pre-revenue biotech firm, progress in clinical trials is the primary way to build value. This step is a necessary hurdle before the company can prove the drug works and eventually seek approval to sell it. While the study is still in an early phase, staying on schedule with patient enrollment is a key sign that the research program is moving as planned.
Source: GlobeNewsWire
The company has a habit of reporting smaller losses than analysts expect, beating estimates in five of the last eight quarters. This suggests management is disciplined with its research spending.
| Expectation | |
|---|---|
| EPS | $-0.14 |
| Revenue | $0M |
Follow Incannex Healthcare Limited to get the latest and most important updates.
Follow IXHL